AI has become a critical tool in diagnosing and managing viral infections such as influenza, respiratory syncytial virus (RSV ...

Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Two recent studies published this week assess the low uptake of respiratory syncytial virus (RSV) vaccine among US veterans ...

(Reuters) -French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio ...

The HHS is betting $500 million on developing a universal flu vaccine that could protect against multiple flu strains.

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced its acquisition of UK-based biotech firm Vicebio in a deal ...

HMPV is considered to be part of the Pneumoviridae viral family, which is the same group Respiratory Syncytial Virus (RSV) is associated with, a Johns Hopkins Center for Health Security report says.